Clinical manifestations of vasculitis and COVID-19 in two patients with eosinophilic granulomatosis with polyangiitis (EGPA)
| Age/ sex | Duration EGPA | Manifestations EGPA | Treatment EGPA | Symptoms COVID-19 | Outcome |
| 33/M | 1 year | Nasal polyposis, sinusitis, asthma, pulmonary infiltrates, rashes, lacrimal gland involvement, MPO-ANCA positive | Prednisone 7 mg, mepolizumab 300 mg SQ Q4 weeks, omalizumab 150 mg SQ Q4 weeks | Fatigue, myalgias, headache, sore throat, fevers, chills, cough, diarrhoea, anosmia, lack of taste | Resolution after 14 days, no flare asthma or EGPA |
| 52/M | 3 years | Nasal polyposis, sinusitis, asthma, bronchiectasis, rashes, splinter haemorrhages, ANCA negative | Prednisone 2.5 mg alternating with 5 mg every other day, mepolizumab 300 mg SQ every 4 weeks | Fatigue, myalgias, fever, headache, nasal congestion, cough, decreased sense of smell | Resolution after 10 days, no flare asthma or EGPA |
.ANCA, antineutrophil cytoplasmic antibody; M, male; MPO, myeloperoxidase; SQ, subcutaneous.